0	8	Retinoid	Retinoid	NNP
9	10	X	X	NNP
11	19	receptor	receptor	NN
20	21	(	(	(
21	24	RXR	RXR	NNP
24	25	)	)	)
26	41	agonist-induced	agonist-induced	JJ
42	52	activation	activation	NN
53	55	of	of	IN
56	73	dominant-negative	dominant-negative	JJ
74	86	RXR-retinoic	rxr-retinoic	JJ
87	91	acid	acid	NN
92	100	receptor	receptor	NN
101	109	alpha403	alpha403	NN
110	122	heterodimers	heterodimer	NNS
123	125	is	be	VBZ
126	141	developmentally	developmentally	RB
142	151	regulated	regulate	VBN
152	158	during	during	IN
159	166	myeloid	myeloid	JJ
167	182	differentiation	differentiation	NN
182	183	.	.	.

185	188	The	the	DT
189	197	multiple	multiple	JJ
198	206	biologic	biologic	JJ
207	217	activities	activity	NNS
218	220	of	of	IN
221	229	retinoic	retinoic	JJ
230	234	acid	acid	NN
235	236	(	(	(
236	238	RA	RA	NNP
238	239	)	)	)
240	243	are	be	VBP
244	252	mediated	mediate	VBN
253	260	through	through	IN
261	264	RAR	RAR	NNP
265	268	and	and	CC
269	277	retinoid	retinoid	NN
278	279	X	x	NN
280	288	receptor	receptor	NN
289	290	(	(	(
290	293	RXR	RXR	NNP
293	294	)	)	)
295	302	nuclear	nuclear	JJ
303	312	receptors	receptor	NNS
313	317	that	that	WDT
318	326	interact	interact	VBP
327	331	with	with	IN
332	340	specific	specific	JJ
341	344	DNA	dna	NN
345	351	target	target	NN
352	361	sequences	sequence	NNS
362	364	as	as	IN
365	377	heterodimers	heterodimer	NNS
378	379	(	(	(
379	386	RXR-RAR	RXR-RAR	NNP
386	387	)	)	)
388	390	or	or	CC
391	401	homodimers	homodimer	NNS
402	403	(	(	(
403	410	RXR-RXR	RXR-RXR	NNP
410	411	)	)	)
411	412	.	.	.

413	415	RA	RA	NNP
416	424	receptor	receptor	NN
425	435	activation	activation	NN
436	443	appears	appear	VBZ
444	452	critical	critical	JJ
453	455	to	to	TO
456	466	regulating	regulate	VBG
467	476	important	important	JJ
477	484	aspects	aspect	NNS
485	487	of	of	IN
488	501	hematopoiesis	hematopoiesis	NN
501	502	,	,	,
503	508	since	since	IN
509	520	transducing	transduce	VBG
521	522	a	a	DT
523	538	COOH-terminally	cooh-terminally	RB
539	548	truncated	truncate	VBN
549	557	RARalpha	RARalpha	NNP
558	568	exhibiting	exhibit	VBG
569	586	dominant-negative	dominant-negative	JJ
587	595	activity	activity	NN
596	597	(	(	(
597	608	RARalpha403	RARalpha403	NNP
608	609	)	)	)
610	614	into	into	IN
615	621	normal	normal	JJ
622	627	mouse	mouse	NN
628	632	bone	bone	NN
633	639	marrow	marrow	NN
640	649	generates	generate	VBZ
650	663	hematopoietic	hematopoietic	JJ
664	670	growth	growth	NN
671	687	factor-dependent	factor-dependent	JJ
688	692	cell	cell	NN
693	698	lines	line	NNS
699	705	frozen	freeze	VBN
706	708	at	at	IN
709	712	the	the	DT
713	724	multipotent	multipotent	JJ
725	735	progenitor	progenitor	NN
736	737	(	(	(
737	740	EML	EML	NNP
740	741	)	)	)
742	744	or	or	CC
745	754	committed	commit	VBN
755	767	promyelocyte	promyelocyte	NN
768	769	(	(	(
769	773	MPRO	mpro	NN
773	774	)	)	)
775	781	stages	stage	NNS
781	782	.	.	.

783	795	Nevertheless	nevertheless	RB
795	796	,	,	,
797	807	relatively	relatively	RB
808	812	high	high	JJ
812	813	,	,	,
814	829	pharmacological	pharmacological	JJ
830	844	concentrations	concentration	NNS
845	847	of	of	IN
848	850	RA	RA	NNP
851	852	(	(	(
852	853	1	1	CD
854	856	to	to	TO
857	859	10	10	CD
860	861	&	&	CC
861	866	mgr;M	mgr;M	NNP
866	867	)	)	)
868	876	overcome	overcome	VBP
877	882	these	these	DT
883	898	differentiation	differentiation	NN
899	905	blocks	block	NNS
906	909	and	and	CC
910	916	induce	induce	VBP
917	925	terminal	terminal	JJ
926	938	granulocytic	granulocytic	JJ
939	954	differentiation	differentiation	NN
955	957	of	of	IN
958	961	the	the	DT
962	966	MPRO	mpro	NN
967	980	promyelocytes	promyelocyte	NNS
981	986	while	while	IN
987	999	potentiating	potentiate	VBG
1000	1013	interleukin-3	interleukin-3	NN
1014	1015	(	(	(
1015	1028	IL-3)-induced	il-3)-induced	JJ
1029	1039	commitment	commitment	NN
1040	1042	of	of	IN
1043	1046	EML	EML	NNP
1047	1052	cells	cell	NNS
1053	1055	to	to	TO
1056	1059	the	the	DT
1060	1080	granulocyte/monocyte	granulocyte/monocyte	NN
1081	1088	lineage	lineage	NN
1088	1089	.	.	.

1090	1092	In	in	IN
1093	1096	the	the	DT
1097	1104	present	present	JJ
1105	1110	study	study	NN
1110	1111	,	,	,
1112	1114	we	we	PRP
1115	1123	utilized	utilize	VBD
1124	1128	RXR-	rxr-	NN
1129	1132	and	and	CC
1133	1145	RAR-specific	rar-specific	JJ
1146	1154	agonists	agonist	NNS
1155	1158	and	and	CC
1159	1170	antagonists	antagonist	NNS
1171	1173	to	to	TO
1174	1183	determine	determine	VB
1184	1187	how	how	WRB
1188	1190	RA	RA	NNP
1191	1200	overcomes	overcome	VBZ
1201	1204	the	the	DT
1205	1222	dominant-negative	dominant-negative	JJ
1223	1231	activity	activity	NN
1232	1234	of	of	IN
1235	1238	the	the	DT
1239	1248	truncated	truncate	VBN
1249	1257	RARalpha	RARalpha	NNP
1258	1260	in	in	IN
1261	1266	these	these	DT
1267	1276	different	different	JJ
1277	1284	myeloid	myeloid	JJ
1285	1298	developmental	developmental	JJ
1299	1305	stages	stage	NNS
1305	1306	.	.	.

1307	1319	Unexpectedly	unexpectedly	RB
1319	1320	,	,	,
1321	1323	we	we	PRP
1324	1332	observed	observe	VBD
1333	1337	that	that	IN
1338	1340	an	an	DT
1341	1353	RXR-specific	rxr-specific	JJ
1353	1354	,	,	,
1355	1361	rather	rather	RB
1362	1366	than	than	IN
1367	1369	an	an	DT
1370	1382	RAR-specific	rar-specific	JJ
1382	1383	,	,	,
1384	1391	agonist	agonist	NN
1392	1399	induces	induce	VBZ
1400	1408	terminal	terminal	JJ
1409	1421	granulocytic	granulocytic	JJ
1422	1437	differentiation	differentiation	NN
1438	1440	of	of	IN
1441	1445	MPRO	mpro	NN
1446	1459	promyelocytes	promyelocyte	NNS
1459	1460	,	,	,
1461	1464	and	and	CC
1465	1469	this	this	DT
1470	1485	differentiation	differentiation	NN
1486	1488	is	be	VBZ
1489	1499	associated	associate	VBN
1500	1504	with	with	IN
1505	1515	activation	activation	NN
1516	1518	of	of	IN
1519	1522	DNA	DNA	NNP
1523	1531	response	response	NN
1532	1540	elements	element	NNS
1541	1554	corresponding	correspond	VBG
1555	1557	to	to	TO
1558	1565	RAR-RXR	rar-rxr	NN
1566	1578	heterodimers	heterodimer	NNS
1579	1585	rather	rather	RB
1586	1590	than	than	IN
1591	1598	RXR-RXR	rxr-rxr	JJ
1599	1609	homodimers	homodimer	NNS
1609	1610	.	.	.

1611	1615	This	this	DT
1616	1619	RXR	RXR	NNP
1620	1627	agonist	agonist	NN
1628	1636	activity	activity	NN
1637	1639	is	be	VBZ
1640	1647	blocked	block	VBN
1648	1650	by	by	IN
1651	1663	RAR-specific	rar-specific	JJ
1664	1675	antagonists	antagonist	NNS
1675	1676	,	,	,
1677	1687	suggesting	suggest	VBG
1688	1697	extensive	extensive	JJ
1698	1708	cross-talk	cross-talk	NN
1709	1716	between	between	IN
1717	1720	the	the	DT
1721	1729	partners	partner	NNS
1730	1732	of	of	IN
1733	1736	the	the	DT
1737	1740	RXR	RXR	NNP
1741	1753	-RARalpha403	-raralpha403	NN
1754	1765	heterodimer	heterodimer	NN
1765	1766	.	.	.

1767	1769	In	in	IN
1770	1778	contrast	contrast	NN
1778	1779	,	,	,
1780	1782	in	in	IN
1783	1786	the	the	DT
1787	1791	more	more	RBR
1792	1800	immature	immature	JJ
1800	1801	,	,	,
1802	1813	multipotent	multipotent	JJ
1814	1817	EML	EML	NNP
1818	1823	cells	cell	NNS
1824	1826	we	we	PRP
1827	1835	observed	observe	VBD
1836	1840	that	that	IN
1841	1845	this	this	DT
1846	1858	RXR-specific	rxr-specific	JJ
1859	1866	agonist	agonist	NN
1867	1869	is	be	VBZ
1870	1878	inactive	inactive	JJ
1879	1885	either	either	CC
1886	1888	in	in	IN
1889	1901	potentiating	potentiate	VBG
1902	1915	IL-3-mediated	il-3-mediated	JJ
1916	1926	commitment	commitment	NN
1927	1929	of	of	IN
1930	1933	EML	EML	NNP
1934	1939	cells	cell	NNS
1940	1942	to	to	TO
1943	1946	the	the	DT
1947	1958	granulocyte	granulocyte	NN
1959	1966	lineage	lineage	NN
1967	1969	or	or	CC
1970	1972	in	in	IN
1973	1988	transactivating	transactivate	VBG
1989	1996	RAR-RXR	RAR-RXR	NNP
1997	2005	response	response	NN
2006	2014	elements	element	NNS
2014	2015	.	.	.

2016	2019	RA-	RA-	NNP
2020	2029	triggered	trigger	VBD
2030	2045	GALdbd-RARalpha	GALdbd-RARalpha	NNP
2046	2052	hybrid	hybrid	NN
2053	2061	activity	activity	NN
2062	2064	in	in	IN
2065	2070	these	these	DT
2071	2076	cells	cell	NNS
2077	2086	indicates	indicate	VBZ
2087	2091	that	that	IN
2092	2095	the	the	DT
2096	2107	multipotent	multipotent	JJ
2108	2111	EML	EML	NNP
2112	2117	cells	cell	NNS
2118	2124	harbor	harbor	VBP
2125	2136	substantial	substantial	JJ
2137	2144	nuclear	nuclear	JJ
2145	2152	hormone	hormone	NN
2153	2161	receptor	receptor	NN
2162	2173	coactivator	coactivator	NN
2174	2182	activity	activity	NN
2182	2183	.	.	.

2184	2191	However	however	RB
2191	2192	,	,	,
2193	2196	the	the	DT
2197	2204	histone	histone	NN
2205	2216	deacetylase	deacetylase	NN
2217	2218	(	(	(
2218	2222	HDAC	HDAC	NNP
2222	2223	)	)	)
2224	2233	inhibitor	inhibitor	NN
2234	2246	trichostatin	trichostatin	NN
2247	2248	A	a	NN
2249	2256	readily	readily	RB
2257	2266	activates	activate	VBZ
2267	2269	an	an	DT
2270	2277	RXR-RAR	rxr-rar	NN
2278	2286	reporter	reporter	NN
2287	2296	construct	construct	NN
2297	2299	in	in	IN
2300	2303	the	the	DT
2304	2315	multipotent	multipotent	JJ
2316	2319	EML	EML	NNP
2320	2325	cells	cell	NNS
2326	2329	but	but	CC
2330	2333	not	not	RB
2334	2336	in	in	IN
2337	2340	the	the	DT
2341	2350	committed	commit	VBN
2351	2355	MPRO	mpro	NN
2356	2369	promyelocytes	promyelocyte	NNS
2369	2370	,	,	,
2371	2381	indicating	indicate	VBG
2382	2386	that	that	IN
2387	2398	differences	difference	NNS
2399	2401	in	in	IN
2402	2417	HDAC-containing	hdac-containing	JJ
2418	2427	repressor	repressor	NN
2428	2437	complexes	complex	NNS
2438	2440	in	in	IN
2441	2446	these	these	DT
2447	2450	two	two	CD
2451	2458	closely	closely	RB
2459	2466	related	related	JJ
2467	2470	but	but	CC
2471	2479	distinct	distinct	JJ
2480	2493	hematopoietic	hematopoietic	JJ
2494	2502	lineages	lineage	NNS
2503	2508	might	might	MD
2509	2516	account	account	VB
2517	2520	for	for	IN
2521	2524	the	the	DT
2525	2537	differential	differential	JJ
2538	2548	activation	activation	NN
2549	2551	of	of	IN
2552	2555	the	the	DT
2556	2571	RXR-RARalpha403	rxr-raralpha403	NN
2572	2584	heterodimers	heterodimer	NNS
2585	2589	that	that	WDT
2590	2592	we	we	PRP
2593	2601	observed	observe	VBD
2602	2604	at	at	IN
2605	2610	these	these	DT
2611	2620	different	different	JJ
2621	2627	stages	stage	NNS
2628	2630	of	of	IN
2631	2638	myeloid	myeloid	JJ
2639	2650	development	development	NN
2650	2651	.	.	.